Dualyx Company Profile

Background

Overview:
Dualyx is a Ghent-based biotechnology company dedicated to developing innovative therapies for autoimmune diseases. Founded in 2020 by Dr. Luc Van Rompaey, the company emerged from a collaborative model involving Wurzburg University, Argenx, VIB, Ghent University, and KU Leuven. Dualyx focuses on creating novel immune modulators, particularly targeting regulatory T cells (Tregs), to restore immune system balance in patients with difficult-to-treat autoimmune conditions.

Key Strategic Focus

Core Objectives:
Dualyx aims to develop first-in-class therapeutics that modulate the immune system by selectively activating Tregs. This approach seeks to suppress unwanted autoimmune reactions, offering potential long-term or curative treatments for autoimmune disease patients.

Areas of Specialization:

• TNFR2 Agonists: Development of antibody agonists targeting Tumor Necrosis Factor Receptor 2 (TNFR2), a critical component in immune modulation.

• Treg Expansion Therapies: Innovative strategies to expand and activate Treg populations in vivo, aiming to restore immune homeostasis.

Key Technologies Utilized:

• Llama-Derived Antibodies: Utilization of multivalent antibodies derived from llamas to target TNFR2, inducing selective activation of Tregs.

• State-of-the-Art Antibody Development: Advanced techniques to create highly selective and potent immune modulators.

Primary Markets Targeted:
Dualyx focuses on addressing a broad range of autoimmune diseases, including:

• Rheumatoid Arthritis

• Inflammatory Bowel Disease

• Multiple Sclerosis

• Psoriasis

• Graves' Disease

Financials and Funding

Funding History:

• Seed Round (March 2020): Raised €7 million from investors including V-Bio Ventures, BioGeneration Ventures (BGV), PMV, VIB, High-Tech Gründerfonds (HTGF), and Gemma Frisius Fund (GFF).

• Series A Financing (May 2023): Secured €40 million ($44 million) co-led by Fountain Healthcare Partners, Forbion, and Andera Partners, with continued support from existing investors.

Notable Investors:

• Fountain Healthcare Partners

• Forbion

• Andera Partners

• V-Bio Ventures

• BioGeneration Ventures (BGV)

• PMV

• VIB

• High-Tech Gründerfonds (HTGF)

• Gemma Frisius Fund (GFF)

Utilization of Capital:
The funds are allocated to advance the lead program, DT-001, into early clinical proof-of-concept phases and to develop additional Treg-focused programs in early-stage development.

Pipeline Development

Lead Program:

• DT-001: An antibody agonist targeting TNFR2, currently in investigational new drug (IND)-enabling studies. Preclinical research has shown promising results, indicating potential as a transformative treatment for various autoimmune diseases.

Additional Programs:

• A pipeline of Treg-focused therapies in early-stage development, aiming to expand and activate Treg populations to restore immune balance.

Anticipated Milestones:

• Progression of DT-001 into early clinical proof-of-concept phases.

• Advancement of additional Treg programs through preclinical development stages.

Technological Platform and Innovation

Proprietary Technologies:

• Llama-Derived Multivalent Antibodies: Development of unique antibodies that act as agonists to TNFR2, selectively activating Tregs.

Significant Scientific Methods:

• In Vivo Treg Expansion: Techniques to increase and activate Treg populations within the body, aiming to suppress unwanted autoimmune reactions.

Leadership Team

• Wouter Verhoeven: Chief Executive Officer

• Background: Extensive experience in biotechnology and venture capital, including roles at NBE-Therapeutics and mAbxience.

• Contributions: Leading Dualyx's strategic direction and operational execution.

• Dr. Luc Van Rompaey: Founder and Chief Scientific Officer

• Background: Former Vice President of Translational Medicine at Argenx.

• Contributions: Overseeing scientific research and development initiatives.

• Dr. Bernard Coulie: Independent Chairman

• Background: CEO of Pliant Therapeutics, with a history of founding and leading successful biotech companies.

• Contributions: Providing strategic guidance and governance oversight.

Leadership Changes

• May 2023: Appointment of Dr. Bernard Coulie as Independent Chairman, bringing extensive experience in biotech leadership.

Competitor Profile

Market Insights and Dynamics:
The autoimmune disease therapeutics market is substantial, with existing treatments like TNF-alpha inhibitors generating significant revenues. There is a growing demand for innovative therapies that offer improved efficacy and safety profiles.

Competitor Analysis:

• Revolo Biotherapeutics: Developing immune modulators for autoimmune diseases.

• Azadyne: Focusing on RNA-based therapies targeting immune modulation.

• Maxion Therapeutics: Specializing in antibody-based treatments for autoimmune conditions.

These companies are also exploring novel approaches to modulate the immune system, highlighting a competitive landscape in the development of next-generation autoimmune therapies.

Strategic Collaborations and Partnerships

Dualyx collaborates with several academic and industrial partners to advance its research and development efforts:

• Academic Partners:

• Wurzburg University

• VIB

• Ghent University

• KU Leuven

• Industrial Partner:

• Argenx

These partnerships facilitate access to cutting-edge research, technologies, and expertise, strengthening Dualyx's innovation capacity.

Operational Insights

Strategic Considerations:
Dualyx's focus on TNFR2 as a therapeutic target offers a differentiated approach in the autoimmune disease market. By leveraging proprietary technologies and strategic collaborations, the company aims to develop therapies with superior efficacy and safety profiles compared to existing treatments.

Competitive Advantages:

• First-in-Class Therapeutics: Development of novel TNFR2 agonists with the potential to transform autoimmune disease treatment.

• Selective Treg Activation: Targeted approach to modulate the immune system without broad immunosuppression.

• Strong Collaborative Network: Partnerships with leading academic and industrial entities enhance research capabilities and innovation.

Strategic Opportunities and Future Directions

Strategic Roadmap:

• Clinical Advancement: Initiate and progress clinical trials for DT-001 and other pipeline candidates.

• Pipeline Expansion: Develop additional Treg-focused therapies targeting various autoimmune diseases.

• Partnership Development: Establish further collaborations to enhance research, development, and commercialization efforts.

Opportunities for Expansion:

• Market Penetration: Address unmet needs in the autoimmune disease market with innovative therapies.

• Technological Innovation: Leverage proprietary technologies to develop next-generation immune modulators.

• Global Reach: Expand operations and partnerships to access international markets and regulatory pathways.

Contact Information

• Website: www.dualyx.com

• Headquarters: Ghent, Belgium

For more information, please visit the company's official website.